“Because the dose of the drug is increased at regular ... Novo Nordisk (NVO) markets both Saxenda, also known as liraglutide, ...

In the new SCALE Kids study, which has been published in the New England Journal of Medicine, a daily 3mg dose of Saxenda reduced the body mass index (BMI) of the children by an average of 5.8% ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

but Saxenda is a higher dose. Although the target for each formulation is the same (the GLP-1 receptor), for glucose control in type 2 diabetes, liraglutide has to (mainly) reach the pancreas.